GRTXD · Galera Therapeutics, Inc. · Debt
$18.99
At close · Aug 3
Return incl. dividend (before tax)
Going-concern doubt
— flagged May 14, 2026
Substantial doubt about the company's ability to continue as a going concern.
“As a result, there is substantial doubt about our ability to continue as a going concern through the 12 months from the date of the filing of this Quarterly Report on Form 10-Q.”View the 10-Q filed May 14, 2026
Market Cap
$15.23M
Shares
802,149
Volume · Aug 3
2447
Avg daily vol (6 sessions)
1267
Debt Profile
Reported borrowing balances, repayment dates and agreement terms, with links to the underlying filings.
Reported debt balances
Each amount keeps its reported scope. Related balance-sheet measures appear under the borrowing they describe.
| Reported balance | As of | Amount | Source |
|---|---|---|---|
| Current long-term debt and lease obligations | 2024-12-31 | USD 0 | 10-K filed 2025-03-31 |
| Operating lease liabilities | 2024-12-31 | USD 0 | 10-K filed 2025-03-31 |
Related accounting measures — not additional borrowingCarrying amounts can reflect issuance costs or discounts. Differences between these measures are not necessarily repayments due within a year.
| |||
Instrument and agreement coverage is incomplete. Additional filings are awaiting review.
Covenants
Covenant terms have not yet been verified for this profile.
The balance figures do not establish whether covenants apply or whether the company complies with them.
Loans, facilities and notes
The instrument breakdown is not yet verified. Read the debt note in the linked report for borrowing terms and maturity conditions.